Implementation of Rotavirus Surveillance and Vaccine Introduction — World Health Organization African Region, 2007–2016

Jason M. Mwenda, PhD1; Rachel M. Burke, PhD2,3; Keith Shaba, MPH1; Richard Mihigo, MD1; Mable Carole Tevi-Benissan, MD1; Mutale Mumba, MBChB1; Joseph Nsiari-Muzeyi Biey, MD1; Dah Cheikh, MD1; Alain Poy, MSc1; Felicitas R. Zawaira, MD1; Negar Aliabadi, MD2; Jacqueline E. Tate, PhD2; Terri Hyde, MD5; Adam L. Cohen, MD4; Umesh D. Parashar, MBBS2 (View author affiliations)

View suggested citation

Summary

What is already known about this topic?

Rotavirus is a leading cause of severe pediatric diarrhea worldwide, and a disproportionate number of deaths occur in countries in the World Health Organization (WHO) African Region. WHO recommends rotavirus vaccination for all infants worldwide.

What is added by this report?

As of December 2016, 31 of 47 (66%) countries in the WHO African Region had introduced rotavirus vaccination into their national schedules. Among these countries, the overall coverage for the completed series of rotavirus vaccination was 77% in 2016. In 12 countries with available sentinel hospital surveillance data before and after rotavirus vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% to 26%.

What are the implications for public health practice?

Continued commitment to improving rotavirus vaccination coverage in the WHO African Region should contribute to reducing the morbidity and mortality associated with this disease. Maintaining and enhancing the existing surveillance network will be critical to the ability to measure vaccine impact.


Article Metrics
Altmetric:
Related Materials

Rotavirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among children aged <5 years in sub-Saharan Africa in 2013 (1). In 2009, the World Health Organization (WHO) recommended rotavirus vaccination for all infants worldwide (2). Two rotavirus vaccines are currently licensed globally: the monovalent Rotarix vaccine (RV1, GlaxoSmithKline; 2-dose series) and the pentavalent RotaTeq vaccine (RV5, Merck; 3-dose series). This report describes progress of rotavirus vaccine introduction (3), coverage (using estimates from WHO and the United Nations Children’s Fund [UNICEF]) (4), and impact on pediatric diarrhea hospitalizations in the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotavirus vaccine, including 26 that introduced RV1 and five that introduced RV5. Among these countries, rotavirus vaccination coverage (completed series) was 77%, according to WHO/UNICEF population-weighted estimates. In 12 countries with surveillance data available before and after vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% preintroduction to 26% following rotavirus vaccine introduction. These results support introduction of rotavirus vaccine in the remaining countries in the region and continuation of rotavirus surveillance to monitor impact.

The status of rotavirus vaccine introduction and 2016 WHO/UNICEF estimates of national vaccination coverage were obtained from the WHO repository (3,4). Among African Region countries that have introduced rotavirus vaccine into their national Expanded Programs on Immunization, most recommend that rotavirus doses coincide with administration of the infant doses of diphtheria and tetanus toxoids and pertussis (DTP) vaccine (at ages 6 and 10 weeks for RV1 and at ages 6, 10, and 14 weeks for RV5); most countries are using RV1 (5). Because the WHO/UNICEF estimates do not include a coverage estimate for the first dose of rotavirus vaccine or the second dose of DTP vaccine, rotavirus vaccination coverage (completed series of either 2 RV1 or 3 RV5 doses) was compared with first-dose and third-dose coverage for DTP. Countries that have introduced rotavirus vaccine were grouped by year of vaccine introduction for analysis.

Rotavirus surveillance data were collected through sentinel hospitals participating in the African Rotavirus Surveillance Network (ARSN), which was established in four countries in 2006 and had expanded to 29 countries by 2016 (Figure) (6). Surveillance staff members at sentinel sites in ARSN enroll children aged <5 years who are hospitalized for acute diarrhea (≥3 looser than normal stools in a 24-hour period before hospitalization, with duration of illness ≤7 days before hospitalization) and collect a stool specimen, which is tested for rotavirus using an enzyme immunoassay. Countries were included in this analysis if their sites collected and tested at least 80 specimens over at least 11 months in a given year. The percentage of tested specimens that were positive for rotavirus was calculated in the vaccine preintroduction and postintroduction periods, by country. The year of rotavirus vaccine introduction was considered a transition period and was excluded from calculations.

Overall, 31 (66%) countries in the region had introduced rotavirus vaccine into their national immunization schedules by December 2016, with 26 introducing RV1 and five introducing RV5 (Table 1). Among all countries, completed series rotavirus vaccination coverage was 77% (population-weighted average); national coverage ranged from 24% (Sao Tome and Principe, 2016 introduction) to 98% (Rwanda, 2012 introduction). When grouping by year of vaccine introduction, the highest overall population-weighted coverage (82%) was in countries that introduced the vaccine before 2014. These same countries also had the smallest average percentage-point difference between completed rotavirus vaccination coverage and DTP1 coverage (overall, 11 percentage points less than DTP1).

Surveillance data were available for 12 and 18 countries during the vaccine preintroduction and postintroduction periods, respectively (Table 2). The average percentage of tested stool specimens that were positive for rotavirus during the vaccine preintroduction period was 41%, ranging from 20% (Ethiopia) to 51% (Togo). During the vaccine postintroduction period, the average percentage of rotavirus-positive specimens was 24%, ranging from 12% (Madagascar) to 41% (Mauritius). In the 12 countries with both vaccine preintroduction and postintroduction data, rotavirus positivity declined by 33% overall (range = 2%–62%), from 39% in the preintroduction period to 26% in the postintroduction period (p<0.001); in these countries, the overall population-weighted 2016 completed rotavirus vaccination series coverage was 82%. In 2016, the overall percentage of positive rotavirus stool specimens was 26% in countries that had introduced the vaccine in 2015 or earlier, and 43% in countries that had not yet introduced the vaccine (p<0.001).

Discussion

Countries in the WHO African Region have made significant progress in the introduction of rotavirus vaccines, with 31 (66%) of 47 member countries having introduced rotavirus vaccine into their national schedules by December 2016. In 2016, the overall completed series rotavirus vaccination coverage in these countries was 77%, which was lower than coverage for DTP1 and DTP3. Some of this difference might be attributable to challenges that are common to new vaccine introduction (e.g., it can take time for all vaccination clinics to have reliable cold chain space and a steady stock of a new vaccine). In addition, challenges specific to the recording and reporting of coverage for new vaccines include mid-year introductions, unavailability of updated data tools, and inadequate orientation of health workers on use of vaccine tally sheets. Another factor specific to rotavirus is the issue of age restrictions. Because of concerns about a potential increased risk for intussusception in older infants who receive the vaccine, WHO initially recommended that rotavirus vaccination be administered only to children aged ≤32 weeks (2). In 2013, WHO recommended lifting these restrictions based on new data and a risk-benefit analysis (7); however, some countries, or some health workers, might still be administering rotavirus vaccine with age restrictions. Additional research is needed to better understand the impact of lifting age restrictions on coverage, and the difference between rotavirus and DTP vaccination coverage.

Surveillance data from ARSN indicate that, among countries with data available both preceding and following rotavirus vaccine introduction, the proportion of rotavirus-positive hospitalizations for diarrhea among children aged <5 years declined 33% following rotavirus vaccine introduction; overall declines were especially notable in countries that had introduced rotavirus vaccine before 2015. These results are particularly encouraging given rotavirus vaccines’ lower efficacy in low-income settings (50%–64% efficacy) than in high-income and middle-income settings (85%–100% efficacy) (8), which had raised concerns about the public health impact of their introduction. However, consistent with recent global analyses demonstrating substantial rotavirus vaccine impact across country income strata (9), the present analysis suggests that rotavirus vaccination has had a meaningful impact on rotavirus disease in Africa.

Sixteen countries in the WHO African Region had not yet introduced rotavirus vaccine as of December 2016; 10 are eligible for Gavi financial support, four of which have received approval. Apart from funding, other factors can affect rotavirus vaccine introduction and subsequent coverage. Coverage with routinely recommended vaccines, as a marker of immunization system function, highlights several countries in the region where the immunization infrastructure needs strengthening. Armed conflict and natural disasters, experienced by several countries in the region, can further stress immunization services. Even under routine circumstances, cold chain management, vaccine transportation, and human resource constraints can negatively affect vaccination coverage; these challenges might be experienced most acutely in countries with large rural populations.

The findings in this report are subject to at least five limitations. First, UNICEF/WHO coverage estimates are based on the best estimates of a combination of administrative data and survey data, each of which might be subject to overreporting or underreporting. Other factors potentially causing a discrepancy between rotavirus coverage and DTP coverage include the inability to compare the final dose of RV1 to the second dose of DTP, and the lack of data on coverage with the first dose of rotavirus vaccines. Second, although protocols for rotavirus surveillance are standardized across the entire network, there are a limited number of surveillance sites in each country; these might not be representative of pediatric diarrheal illness across the country and might provide an incomplete picture of impact. Third, immunization and surveillance data quality vary among countries. Fourth, not all sites have been able to conduct continuous rotavirus disease surveillance, and data were not included in these results if analysis criteria were not met. Finally, rotavirus surveillance data are not available for all countries before introduction, limiting the ability to assess vaccine impact in countries without vaccine preintroduction data or those that are not part of the ARSN.

Overall, substantial progress has been made in the introduction of rotavirus vaccine and surveillance for rotavirus disease in countries in the WHO African Region. In countries where rotavirus vaccine has been introduced, a substantial decline in the percentage of rotavirus-associated pediatric diarrhea hospitalizations was observed. As rotavirus vaccination coverage increases, an even greater decline might be expected; however, continuous surveillance is a critical component of measuring vaccine impact. Financial support from Gavi, the Vaccine Alliance, has played a key role in rotavirus vaccine introduction and rotavirus surveillance in the region (10). Nonetheless, Gavi support will not continue indefinitely; as their economies improve, countries will graduate from Gavi support and begin to finance the total cost of the vaccine. Maintaining surveillance for rotavirus disease will provide important data necessary to promoting continued investment in rotavirus vaccination. Rotavirus vaccination is a critical element in reducing child deaths from diarrhea and contributing to the improvement of child health globally.

Acknowledgment

Gavi, the Vaccine Alliance.

Conflict of Interest

No conflicts of interest were reported.

Corresponding author: Jason M. Mwenda, jmwenda@who.int, +47-241-39669.


1World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo; 2Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC; 3Epidemic Intelligence Service, CDC; 4Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland; 5Global Immunization Division, Center for Global Health, CDC.

References

  1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD; World Health Organization–Coordinated Global Rotavirus Surveillance Network. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis 2016;62(Suppl 2):S96–105. CrossRefExternal PubMedExternal
  2. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009;84:533–40. PubMedExternal
  3. World Health Organization. Immunization vaccines and biologicals database, September 2016. Geneva, Switzerland: World Health Organization; 2016. http://www.who.int/immunization/monitoring_surveillance/data/en/External
  4. World Health Organization (WHO). WHO/UNICEF estimates of national immunization coverage. Geneva, Switzerland: World Health Organization/United Nations Children’s Fund; 2016. http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.htmlExternal
  5. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2017 global summary. Geneva, Switzerland: World Health Organization; 2017. http://apps.who.int/immunization_monitoring/globalsummary/schedulesExternal
  6. Mwenda JM, Tate JE, Parashar UD, et al. African rotavirus surveillance network: a brief overview. Pediatr Infect Dis J 2014;33(Suppl 1):S6–8. CrossRefExternal PubMedExternal
  7. World Health Organization. Rotavirus vaccines. WHO position paper—January 2013. Wkly Epidemiol Rec 2013;88:49–64. PubMedExternal
  8. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012;11:CD008521. PubMedExternal
  9. Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis 2017;215:1666–72. CrossRefExternal PubMedExternal
  10. Gavi, the Vaccine Alliance. Countries approved for support. Geneva, Switzerland, Gavi; 2017. http://www.gavi.org/results/countries-approved-for-support/External
Return to your place in the textFIGURE. Rotavirus vaccine introduction status — World Health Organization (WHO) African Region, 2016
The figure above is a map of the World Health Organization African Region, showing which countries had introduced or not introduced rotavirus vaccine as of 2016, and which countries were members of the African Rotavirus Surveillance Network.

The figure above is a map of the World Health Organization African Region, showing which countries had introduced or not introduced rotavirus vaccine as of 2016, and which countries were members of the African Rotavirus Surveillance Network.

 

Return to your place in the textTABLE 1. Percentage coverage with first and third DTP vaccine doses and completed rotavirus (RV) vaccination series — World Health Organization African Region, 2016
Country Year RV vaccine introduced RV vaccine type Coverage (%) Percentage-point difference in coverage
DTP1 DTP3 RV (completed series) DTP1 versus completed RV DTP3 versus completed RV
Countries introducing RV vaccine 2009–2013* 93 88 82 11 6
South Africa 2009 RV1 78 66 73 5 −7
Botswana 2012 RV1 98 95 95 3 0
Ghana 2012 RV1 94 93 94 0 −1
Malawi 2012 RV1 89 84 81 8 3
Rwanda 2012 RV5 99 98 98 1 0
Tanzania 2012 RV1 99 97 96 3 1
Burkina Faso 2013 RV5 95 91 91 4 0
Burundi 2013 RV1 97 94 96 1 −2
Ethiopia 2013 RV1 86 77 63 23 14
Gambia 2013 RV5 99 95 95 4 0
Zambia 2013 RV1 99 91 90 9 1
Countries introducing RV vaccine 2014* 89 79 73 16 6
Angola 2014 RV1 79 64 53 26 11
Cameroon 2014 RV1 92 85 80 12 5
Republic of the Congo 2014 RV1 85 80 80 5 0
Eritrea 2014 RV1 97 95 96 1 −1
Kenya 2014 RV1 96 89 74 22 15
Madagascar 2014 RV1 84 77 78 6 −1
Mali 2014 RV5 86 68 60 26 8
Mauritania 2014 RV1 87 73 73 14 0
Namibia 2014 RV1 98 92 86 12 6
Niger 2014 RV1 87 67 61 26 6
Senegal 2014 RV1 96 93 93 3 0
Sierra Leone 2014 RV1 97 84 95 2 −11
Togo 2014 RV1 93 89 90 3 −1
Zimbabwe 2014 RV1 94 90 91 3 −1
Countries introducing RV vaccine 2015–2016* 92 81 73 19 8
Guinea-Bissau 2015 RV1 95 87 61 34 26
Mauritius 2015 RV1 97 96 92 5 4
Mozambique 2015 RV1 90 80 76 14 4
Swaziland 2015 RV1 96 90 95 1 −5
Liberia 2016 RV1 99 79 48 51 31
Sao Tome and Principe 2016 RV5 97 96 24 73 72

Abbreviations: DTP = diphtheria and tetanus toxoids and pertussis; DTP1 = first dose of DTP vaccine; DTP3 = third dose of DTP vaccine; RV1 = monovalent RV vaccine (Rotarix); RV5 = pentavalent RV vaccine (RotaTeq).
* Summary data for introduction period are population-weighted averages.
Country initially introduced RV5, but switched to RV1 in 2017.

Return to your place in the textTABLE 2. Rotavirus (RV) stool specimen surveillance results, by country and vaccine introduction status — World Health Organization African Region, 2008–2015
Country Year RV vaccine introduced Vaccine preintroduction period Vaccine postintroduction period % decline in RV positivity*
Years included RV specimens tested No (%) positive Years included RV specimens tested No. (%) positive
Countries introducing 2012–2013 9,916 3,685 (37)   — 20,389 5,544 (27) 27%
Ghana 2012 2008, 2010–2011 2,374 1,161 (49)   2013–2016 1,494 405 (27) 45%
Rwanda 2012 2011 240 121 (50)   2013–2015 2,237 447 (20) 60%
Tanzania 2012 2009–2010 852 308 (36)   2013–2016 8,615 2,186 (25) 30%
Zambia 2012 2007–2011 4,519 1,700 (38)   2013–2016 5,227 1,700 (33) 14%
Burkina Faso 2013 NS NS NS   2014–2016 1,889 615 (33) NS
Ethiopia 2013 2008–2012 1,931 395 (20)   2014–2016 822 165 (20) 2%
Gambia 2013 NS NS NS   2014 105 26 (25) NS
Countries introducing 2014 14,062 5,628 (40)   — 6,704 1,552 (23) 42%
Angola 2014 NS NS NS   2015 229 41 (18) NS
Cameroon 2014 2008–2013 3,449 1,398 (41)   2015–2016 973 197 (20) 50%
Kenya 2014 2007–2013 4,406 1546 (35)   2015–2016 688 158 (23) 35%
Madagascar 2014 NS NS NS   2015–2016 451 56 (12) NS
Niger 2014 NS NS NS   2016 168 22 (13) NS
Senegal 2014 2011–2013 374 159 (43)   2015–2016 235 38 (16) 62%
Togo 2014 2008, 2010–2013 1,028 526 (51)   2015–2016 319 119 (37) 27%
Zimbabwe 2014 2008–2009, 2011–2013 4,805 1,999 (42)   2015–2016 3,641 921 (25) 39%
Countries Introducing 2015 1,319 626 (47)   — 1,081 330 (31) 36%
Mauritius 2015 2010–2014 1,203 578 (48)   2016 570 235 (41) 14%
Mozambique 2015 NS NS NS   2016 420 68 (16) NS
Swaziland 2015 2013 116 48 (41)   2016 91 27 (30) 28%

Abbreviations: NS = No surveillance data available (surveillance not started or data do not meet analysis criteria); RV = rotavirus vaccine.
* Calculated only for countries with data on rotavirus vaccine preintroduction and postintroduction. Percentage declines might not correspond to preintroduction and postintroduction percentages because of rounding.


Suggested citation for this article: Mwenda JM, Burke RM, Shaba K, et al. Implementation of Rotavirus Surveillance and Vaccine Introduction — World Health Organization African Region, 2007–2016. MMWR Morb Mortal Wkly Rep 2017;66:1192–1196. DOI: http://dx.doi.org/10.15585/mmwr.mm6643a7External.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In:Cdc-pdf
Page last reviewed: November 2, 2017